Loading
A phase 2 trial of Inavolisib, Ribociclib and Giredestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer is a phase 2 interventional study registered as NCT07054190 by Hoffmann-La Roche, with 120 participants planned, started 2025-09-09 and due to reach its primary completion in 2027-07-31. Interventions recorded: Inavolisib, Ribociclib, Letrozole and Giredestrant.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Giredestrant, Inavolisib, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.